340B hospitals use biosimilar drugs less than other hospitals, which may expose patients to higher out-of-pocket costs, a drug industry funded study concludes.
Pharmaceutical Research and Manufacturers of America released the study last week. Healthcare consulting firm Milliman did the research for
…
Drug company actions to limit 340B pricing through contract and specialty pharmacies are harming 340B hospitals and their patients, according to a new American Hospital Association member survey.
AHA released the results yesterday. More than 300 hospitals were surveyed in April,
…
The 340B statute should be amended to extend discounts to emergency-use drugs to treat COVID-19 as a first step in rebuilding the COVID-19 safety net, an opinion piece published yesterday in the medical journal Health Affairs says.
…
Pressure on Congress to clarify the 340B program is reaching unprecedented levels, health care attorneys at the Manatt law firm said during a webinar Wednesday on the future of the program.
Meanwhile, a new survey by the firm showed that
…
Congress’ nonpartisan research office has issued a four-page backgrounder on litigation over the 340B contract pharmacy program and a two-pager on the entire drug discount program. They could be a sign that 340B hearings and/or bills are coming.
The Congressional
…
More than 1,000 covered entities—double the number in May—are submitting 340B drug claims data to Second Sight Solutions’ 340B ESP platform to be able to keep dispensing manufacturers’ drugs to patients at multiple contract pharmacies, a senior 340B ESP leader
…
Changing the 340B patient definition “might reduce hospitals’ and physicians’ incentives to consolidate,” but to what extent “remains highly uncertain,” the Congressional Budget Office says in a new policy analysis.
House Budget Committee Chair John Yarmuth (D-Ky.) asked CBO to
…
Ryan White Clinics for 340B Access (RWC-340B), a national organization of 340B HIV/AIDS medical providers, has published a detailed rebuttal of several recently published articles criticizing the 340B program. RWC-340B accuses article authors—many of whom are supported by the drug
…
340B disproportionate share hospitals (DSH) in 2020 spent 2.2 times more on outpatient drugs per commercially insured patient than non-340B DSH hospitals and 2.6 times more than other types of 340B hospitals, a new drug industry-funded study shows.
The
A federal watchdog agency wants to know if 340B hospitals give low-income uninsured patients a break on drug prices at their contract and in-house pharmacies as part of the agency’s evaluation of a law that helps some hospitals forced out
…*Sign up for news summaries and alerts from 340B Report